中医补益法在肺癌化疗不良反应治疗中的运用
|
摘要
目的：通过研究中医补益法在肺癌化疗不良反应治疗中的运用,探讨肺癌化疗中如何正确使用补益法扶助机体正气,在明确应用原则和基本要点的基础上,初步揭示其运用的一般规律,以期达到减少不良反应、提高治疗效果、改善患者生活质量的目的,并为临床中西医结合治疗肺癌提供有益的理论指导。
方法：本课题采用文献研究和临床回顾性病例分析的方法,从中西医对肺癌及化疗不良反应的认识、临床补益法如何辨证使用、常用治法及用药等三方面进行研究。论文内容分为三部分：第一部分,通过检索大量最新的国内外文献,探讨肺癌的中西医概念、病因病机、临床表现、诊断治疗及化疗不良反应的中医辨治概况；第二部分,对202例江苏省中医院肿瘤科收取的肺癌化疗中患者病历资料进行研究,以统计学处理为手段,探讨中医辨证分型的基本规律,并通过药物使用频次分析,总结其用药特点。第三部分,在文献和临床研究的基础上,阐明肺癌化疗中中医补益法运用的原则及要点。
结果：中医学认为肺癌大都存在正气亏损、阴阳两虚的基础,加之化疗药物进一步损伤脾胃,脾胃虚衰以致气血生化乏源,更使正气亏虚、气血瘀滞,病症经久不愈。化疗药物损伤机体的机理可归纳为以下几点：①直接损伤机体正气,耗伤气血,损及阴阳,败坏精血,致使正气亏虚；②中伤脾胃,影响脾胃运化功能,导致气血生化乏源；同时,也可因脾失运化,而使痰湿内生；③损及肾脏,影响骨髓,致使肾精不足,骨髓空虚,影响气血精髓之生化；也可导致水液代谢紊乱,产生痰湿之证；④损伤肝脏致使肝阴不足,疏泄失调,导致肝郁气滞,血瘀内阻。本文研究结果表明,从统计数据显示肺癌化疗时中医治疗以补虚为方向,酌情辅以清热化痰、止咳平喘、活血化瘀、软坚散结等干预手段。因而提示：对肺癌化疗中的患者,中医总体的治疗原则为“扶正祛邪”。依据202例收纳病例的统计资料,大致辨证分为12个证型,其治疗方法以“益气养阴、补肺健脾”为基础,再根据患者证型的不同,予以清热、化痰、祛湿、活血化瘀、软坚散结等治法,合理配伍,多法联用,以达到增强化疗疗效、减轻化疗不良反应、提高生存质量、延长生存期等作用。临床运用补益法的原则是辨证施补、灵活变化、补而不滞,并应注意健脾助运、养阴生津、补肺益肾、养中寓调、缓补消积等要点。
结论：中医补益法是肺癌化疗中的重要治法,在辨证基础上灵活选用恰当的补法,对肺癌化疗患者具有重要意义。临床以益气养阴、补肺健脾法最为常用,可酌情配合清热、化痰、祛湿、软坚等治法共同使用。
Objective:To study the application of Chinese Herbal Medicine for the side effects of lung cancer chemotherapy and discuss the effects of Chinese Herbal Medicine in reducing the side effects in order to achieve detoxing, maximizing the benefits of the chemotherapy and improving patients'quality of life.
Method:The discussion consists of three parts. First:Researched and discussed the latest literatures that touched on the concept of Chinese and western medicine, causes of lung cancer, symptoms of lung cancer, diagnosis and treatment. Second:Studied202medical records of the patient with lung cancer at Jiangsu Province Hospital of TCM. Analyzed the data and found patterns on herbal treatment. Third:Based on the literature and clinical research, clarify the principles and main points of Chinese Herbal Medicine on lung cancer chemotherapy.
Results:Chinese Medicine states that lung cancer is based on the decline of Qi and the weakness of both Ying and Yang. When treating with chemotherapy, it hurts spleen and stomach in addition to the Qi. Thus causing a vicious circle that will prolong the illness. The mechanism of chemotherapy will distress the body in the following ways:1. direct harm on Qi2. injure spleen and stomach which affects the digestive systems3. damage kidney which affects marrows and metabolism4. damage liver. The result of analysis points out the direction for treating lung cancer patients with chemotherapy:provide supplement on the weakness of Qi. In addition, the treatments should include clearing heat, the reduction on phlegm and coughing and invigorate the circulation of blood. This concludes the general guideline for treating lung cancer patients with chemotherapy. The study further categorized12types of patients from the research of medical records. With the different types of patient, the Chinese Herbal Medicine should be applied according to the symptoms. This way, it ensures that the benefit of chemotherapy is maximized, side effects of chemotherapy are reduced, and quality of life is improved. Through this study, a general guideline for treating lung cancer patients with chemotherapy can be found and be referenced in the future for other lung cancer studies.
Conclusion:The application of Chinese medicine supplements is an important method in lung cancer chemotherapy. Selection of appropriate tonifying method based on syndrome differentiation, plays an important role in lung cancer patients undergoing chemotherapy. The method of supplementing qi, nourishing yin and strengthening spleen and supplementing lung can be combined with nourishing yin and clearing heat, phlegm, dampness, soft hard treatment.
方法：本课题采用文献研究和临床回顾性病例分析的方法,从中西医对肺癌及化疗不良反应的认识、临床补益法如何辨证使用、常用治法及用药等三方面进行研究。论文内容分为三部分：第一部分,通过检索大量最新的国内外文献,探讨肺癌的中西医概念、病因病机、临床表现、诊断治疗及化疗不良反应的中医辨治概况；第二部分,对202例江苏省中医院肿瘤科收取的肺癌化疗中患者病历资料进行研究,以统计学处理为手段,探讨中医辨证分型的基本规律,并通过药物使用频次分析,总结其用药特点。第三部分,在文献和临床研究的基础上,阐明肺癌化疗中中医补益法运用的原则及要点。
结果：中医学认为肺癌大都存在正气亏损、阴阳两虚的基础,加之化疗药物进一步损伤脾胃,脾胃虚衰以致气血生化乏源,更使正气亏虚、气血瘀滞,病症经久不愈。化疗药物损伤机体的机理可归纳为以下几点：①直接损伤机体正气,耗伤气血,损及阴阳,败坏精血,致使正气亏虚；②中伤脾胃,影响脾胃运化功能,导致气血生化乏源；同时,也可因脾失运化,而使痰湿内生；③损及肾脏,影响骨髓,致使肾精不足,骨髓空虚,影响气血精髓之生化；也可导致水液代谢紊乱,产生痰湿之证；④损伤肝脏致使肝阴不足,疏泄失调,导致肝郁气滞,血瘀内阻。本文研究结果表明,从统计数据显示肺癌化疗时中医治疗以补虚为方向,酌情辅以清热化痰、止咳平喘、活血化瘀、软坚散结等干预手段。因而提示：对肺癌化疗中的患者,中医总体的治疗原则为“扶正祛邪”。依据202例收纳病例的统计资料,大致辨证分为12个证型,其治疗方法以“益气养阴、补肺健脾”为基础,再根据患者证型的不同,予以清热、化痰、祛湿、活血化瘀、软坚散结等治法,合理配伍,多法联用,以达到增强化疗疗效、减轻化疗不良反应、提高生存质量、延长生存期等作用。临床运用补益法的原则是辨证施补、灵活变化、补而不滞,并应注意健脾助运、养阴生津、补肺益肾、养中寓调、缓补消积等要点。
结论：中医补益法是肺癌化疗中的重要治法,在辨证基础上灵活选用恰当的补法,对肺癌化疗患者具有重要意义。临床以益气养阴、补肺健脾法最为常用,可酌情配合清热、化痰、祛湿、软坚等治法共同使用。
Objective:To study the application of Chinese Herbal Medicine for the side effects of lung cancer chemotherapy and discuss the effects of Chinese Herbal Medicine in reducing the side effects in order to achieve detoxing, maximizing the benefits of the chemotherapy and improving patients'quality of life.
Method:The discussion consists of three parts. First:Researched and discussed the latest literatures that touched on the concept of Chinese and western medicine, causes of lung cancer, symptoms of lung cancer, diagnosis and treatment. Second:Studied202medical records of the patient with lung cancer at Jiangsu Province Hospital of TCM. Analyzed the data and found patterns on herbal treatment. Third:Based on the literature and clinical research, clarify the principles and main points of Chinese Herbal Medicine on lung cancer chemotherapy.
Results:Chinese Medicine states that lung cancer is based on the decline of Qi and the weakness of both Ying and Yang. When treating with chemotherapy, it hurts spleen and stomach in addition to the Qi. Thus causing a vicious circle that will prolong the illness. The mechanism of chemotherapy will distress the body in the following ways:1. direct harm on Qi2. injure spleen and stomach which affects the digestive systems3. damage kidney which affects marrows and metabolism4. damage liver. The result of analysis points out the direction for treating lung cancer patients with chemotherapy:provide supplement on the weakness of Qi. In addition, the treatments should include clearing heat, the reduction on phlegm and coughing and invigorate the circulation of blood. This concludes the general guideline for treating lung cancer patients with chemotherapy. The study further categorized12types of patients from the research of medical records. With the different types of patient, the Chinese Herbal Medicine should be applied according to the symptoms. This way, it ensures that the benefit of chemotherapy is maximized, side effects of chemotherapy are reduced, and quality of life is improved. Through this study, a general guideline for treating lung cancer patients with chemotherapy can be found and be referenced in the future for other lung cancer studies.
Conclusion:The application of Chinese medicine supplements is an important method in lung cancer chemotherapy. Selection of appropriate tonifying method based on syndrome differentiation, plays an important role in lung cancer patients undergoing chemotherapy. The method of supplementing qi, nourishing yin and strengthening spleen and supplementing lung can be combined with nourishing yin and clearing heat, phlegm, dampness, soft hard treatment.
引文
[1]Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung canc-er:epidemiology, risk factors, treatment, and survivorship[J]. Mayo Clin Proc,2008,83(5):584-594.
[2]汪英,李锡春.恶性肿瘤放疗、化疗后的中医药应用体会[J].世界中医药,2009,3(4)：97-98.
[3]吴一龙,廖美琳,孙燕,等.中国肺癌临床指引(2005年版).人民卫生出版社,2005.
[4]刘嘉湘,现代中医药应用与研究大系[M].肿瘤科第一版.上海：上海中医药出版社,1996：120.
[5]李连弟,鲁风珠,张思维,等.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997：19(1)：3.
[6]周清华,孙燕.肺癌新理论新技术进展[M].第一版.成都：四川大学出版社,2003：3-7.
[7]李连弟,饶克勤.中国11市县肿瘤发病和死亡登记资料统计分析(1988年-1992年)[J].中国肿瘤,2000；9(10)：435-447.
[8]李连弟,饶克勤,张思维,等.中国12市县1993年-1997年肿瘤发病和死亡登记资料统计分析[J].中国肿瘤,2002：11(9)：497-50.
[9]张思维,陈万青,孔灵芝,等.中国部分市县1998-2002年恶性肿瘤的发病与死亡[J].中国肿瘤,2006：15(7)：430-448.
[10]张思维,陈万青,孔灵芝,等.中国部分市县2003年恶性肿瘤发病年度报告[J].中国肿瘤,2007：16(7)：494-507.
[11]陈万青,张思维,邹小农.中国肺癌发病死亡的估计和流行趋势研究[J].中国肺癌杂志,2010,13(5)：488-493.
[12]杨功焕,王俊芳,万霞,等.影响中国人群疾病死亡因素的定量分析[J].中华流行病学杂志,2005,26(12)：3212-3218.
[13]Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women:age, smok-ing, histology, performance status, stage, initial treatment and survival:Pop-ulation-based study of 20,561 cases[J]. Ann Oncol,2002,13 (7):1087-1093.
[14]Crespo-Leiro MG, Villa-Arranz A, Manito-Lorite N, et al. Lung cancer a erheart transplantation:results from a large multicenter registry[J]. Am J Trans-plant,2011,11 (5): 1035-1040.
[15]尧晓晴,孙世良,刘平,等.1,213例肺癌患者的人群分布特点[J].职业卫生与 病伤,2008,18(1)：9-10.
[16]Mills C A, Potrer M M. Tobacco smokinghabits and cancer of the mouth and respiratory system[J]. Cancer Res,1950,10 (9):539-542.
[17]Centers for Disease Control and Prevention. Tobacco use among adults-United States, 2005[J]. MMWR,2006,55 (42):1145-1148.
[18]Vineis P, Alavanja M, Buffler P, et al. Tobacco and cancer:recent epidemiological evidence[J]. JNCI,2004,96 (2):99-106.
[19]Vineis P, Airoldi L, Veglia F, et al. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study[J]. BMJ,2005,330 (7486):265-266.
[20]Yang P, Allen M S, Aubry M C, et al. Clinical features of 5,628 primary lung cancer patients:experience at Mayo Clinic from 1997 to 2003 [J]. Chest,2005,128 (1):452-462.
[21]杨功焕,马杰民,刘娜,等.中国人群2002年吸烟和被动吸烟的现况调查[J].中华流行病学杂志,2004,25(10)：837-840.
[22]Krinsky N I, Johnson E J. Carotenoidactions and their relation to health and idsease [J]. Mol Aspects Med,2005,26 (6):459-516.
[23]Ruano-Ravina A, Figueiras A, Freire-Garabal M, et al. Antioxidant Vitamins and risk of lung cancer [J]. Curr Pharm Des,2006,12 (5):599-613.
[24]Siems W, Wiswedel I, Saleno C, et al. β-Carotene breakdwom products may impair mitochondrial functions-potential side effects of higy-dose β-carotene supplementation [J]. J NutrBiochem,2005,16 (7):385-397.
[25]Schuller H M, Porter B, Riechert A, et al. Neuroendocrine lung carcinogenesis in hamsters is inhibited by green tea theophylline while the development of adenocarcinomas is promoted:implications for chemoprevention in smokers [J]. Lung Cancer,2004,45 (1): 11-18.
[26]Vittal R, Selvanayagam Z E, Sun Y, et al. Gene expression changes induced by geen tea polyphenol-epigallocatechin-3-gallate in human bronchial 21BES cells analyzed by DNA microarray[J]. Mol Cancer Ther,2004,3 (9):1091-1099.
[27]Sinha R, Kulldorff M, Swanson C A, et al. Dietary heterocyclic amines and the risk of lung cancer among Missouri women [J]. Cancer Res,2000,60 (14):3753-3756.
[28]高国福,姚树详,孙秀娣,等.云南锡矿工肺癌的队列研究[J].中国肺癌杂志,2002,5(2)：81-91.
[29]Essary L R, Vargas S O, Fletcher C D. Primary pleuropulmonary synovial sarcoma: reappraisal of a recently described anatomic subset [J]. Cancer,2002,94(2):459-469.
[30]Minna J D, Roth J A, Gazdar A F. Focus on lung cancer [J]. Cancer Cell,2002,1 (1):49-52.
[31]Hussain S P, Hofseth L J, Harris C C. Tumor suppressor genes:at the crossroads of molecular carcinogenesis, molecular epedemiology and human risk assessment [J]. Lung Cancer,2001,34 (Suppl2):7-15.
[32]Pfeifer G P, Denissenko M F, Olivier M, et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers [J]. Oncogene,2002,21 (48):7435-7451.
[33]Hainaut P, Olivier M, Pfeifer G P. TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke:Lessons from the I ARC TP53 mutation database [J]. Mutagenesis,2001,16 (6):551-553.
[34]吕嘉春,吴中亮,施侣元,等.核苷酸切除修复基因表达低下与肺癌的关系[J].中国公共卫生,2003,19(7)：780-782.
[35]Hirscha F R, Herbst R S, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy [J]. J Clin Oncol,2008,26 (20):3351-3357.
[36]Sequist L V, Bell D W, Lynch T J, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small lung cancer[J]. J Clin Oncol,2007,25 (5): 587-595.
[37]Ciardiello F, Torrora G. EGFR antagonists in cancer treatment[J]. N Engl J Med,2008, 358 (11):1160-1174.
[38]张德超,毛友生,黄国俊.中国肺癌外科治疗概况与进展[J].中国肺癌杂志,2005：8(6)：572-562.
[39]李佩文.肺癌综合诊疗学[M].第一版.北京：中国中医药出版社,2001：295-302.
[40]周清华,孙燕.肺癌新理论新技术进展[M].第一版.成都：四川大学出版社,2003：164-165.
[41]The international adjuvant lung cancer trial collaborative group. Cis Platinbased Adjuvant chemotherapy in Patients with completely reseeted non-Small cell lung cancer[J]. NEJM, 2004:3 (50):351-360.
[42]曾大雄,徐永健.非小细胞肺癌的化疗进展[J].世界临床药物,2009：30(4)：242-247.
[43]Roy S. Herbst Targeted Therapy in Non-Small Cell Lung Cancer. On-cology,2002, 16 (suppl9):19-24.
[44]张晓彤,李龙芸,王树兰,等.吉非替尼治疗晚期非小细胞肺癌疗效观察[J].中华结核和呼吸杂志,2005,25：180-183.
[45]王金万,孙燕,刘永煜,等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4)：283-290.
[46]程翔,童莉.癌生物治疗研究进展[J].现代中西医结合杂志,2006：15(6)： 829-831.
[47]廖美琳,赵家美,杨新法,等.肺癌[M].北京：中国医药科技出版社,2003.
[48]段庚仙.恶性肿瘤化疗的毒副作用及其防治[J].肿瘤研究与临床.2004,10(16)：353-354.
[49]庞香茹.中药治疗恶性肿瘤放化疗后骨髓抑制的临床研究[J].中医学报,2011,4(4)：393-394.
[50]何舒.化疗呕吐研究进展[J].宁夏医学杂志,2003,25(3)：12-16.
[51]刘欣荣,杨怀勇,唐盛得.如何减少放化疗治疗的副作用[M].2010年中国药学大会暨第十届中国药师周论文集.
[52]张娜,曹勇.恶性肿瘤化疗毒副反应从脾肾论治[J].新中医,2010,10(42)10：1-2.
[53]邓海滨,王中奇.徐振晔辨治肺癌经验[J].四川中医,2002,20(6)：1.
[54]赵炜.李佩文治疗肺癌的经验[J].北京中医,2002,21(6)：329.
[55]周晓园,陶凯.顾振东治疗肿瘤的经验[J].中医杂志,1999,40(7)：395.
[56]孙宏新,孙君.周宜强教授诊治肺癌经验[J].中国中医药信息杂志,2000,7(4)：68.
[57]陈延武,樊惠连.胡国良老中医临证经验总结[J].湖南中医杂志,1998,14(3)：27.
[58]洪广样.原发性支气管肺癌中医药治疗的探讨[J].江西中医药,1995,26(6)：3.
[59]骆文斌,吴承玉.肺癌病因病机研究[J].辽宁医药大学学报,2009,11(3)：16-17.
[60]田建辉,施志明.原发性支气管肺癌中医药治疗现状分析[J].四川中医,2003,21(1)：15-17.
[61]唐文秀,张宗歧,林红生,等.中医药治疗晚期原发性非小细胞肺癌的临床观察[J].中医杂志,1994,35(5)：283-285.
[62]刘嘉湘,施志明,徐振华,等.滋阴生津益气温阳法治疗晚期原发性肺腺癌的临床研究[J]中医杂志,1995,36(3)：155.
[63]蒋天佑.肺癌的辨治经验与体会[J].山西中医,2008,24(12)：3-5.
[64]陈锐深,张伦.肺癌578例辨证论治[J].亚洲医药,1997,12(5)：21.
[65]刘振东,吴林生.周维顺治疗肺癌经验[J].浙江中医学院学报,2004,3(28)：39-40.
[66]李东芳.中医辨证治疗晚期非小细胞肺癌32例临床观察[J].四川中医,2003,21(1)： 33.
[67]游捷,施志明.肺积方治疗非小细胞肺癌61例临床疗效评价[J].上海中医药杂志,2005,39(6)：17.
[68]孙玉清,史清华.中医药治疗中晚期肺癌33例[J].新中医,2005,37(8)：34.
[69]孙钢.刘嘉湘辨治肺癌的特色[J].中医杂志,2000,41(2)：75.
[70]范元芳,许秋萍,何伟涛.中医辨证综合治疗非小细胞肺癌临床疗效观察[J].中医药通报,2004,3(4)：47.
[71]陈乃杰.中医辨证配合化疗治疗晚期非小细胞肺癌41例[J].浙江中西医结合杂志,2000,10(1)：14.
[72]周维顺,吴良村,沈敏鹤.肺癌中医治则之我见[J].浙江中医学院学报,1992,16(2)：8-9.
[73]李佩文,张代钊,郝迎旭,等.平肺方治疗非小细胞肺癌109例临床观察[J].中医杂志,1995,36(2)：87.
[74]吴兰康.吴氏抗癌散结膏及抗癌扶正散治疗中晚期肺癌62例观察[J].实用中医药杂志,1994,10(3)：15.
[75]章永红,金树文.扶正软坚汤治疗肺癌临床观察[J].河南中医,1998,18(2)：44.
[76]刘长华.中药宁肺片治疗晚期肺癌临床观察[J].天津中医,1997,14(5)：208-209.
[77]李大鹏.康莱特注射液治疗原发性肺癌临床报告[J].中医杂志,1996,37(7)：413.
[78]张中华,任清宇.中药消癌平口服液治疗晚期肺癌的疗效观察[J].中华医学实践杂志,2007,6(7)：640-641.
[79]蔡红兵,代方国,闵清芬,等.中医药配合放疗治疗肺癌的临床研究[J].第一军医大学学报,2002,22(12)：1112.
[80]周荣耀,吴丽英,徐中伟,等.夏枯草注射液配合闭塞引流方法治疗肺癌胸水26例临床观察[J].中医杂志,1998,39(11)：662.
[81]杨爱光,王兴双.安肺膏外贴治疗肺癌[J].中医外治杂志,1996,13(2)：31.
[82]杨葆康,姜仁成,灵仙丹.熏吸疗法治疗中晚期肺癌66例[J].辽宁中医杂志,1994,21(7)：323.
[83]李永光,赵泉林,张盂香,等.气至病所治疗肺癌的初步研究[J].中国针灸,1989,2(3)：24.
[84]杨维泓,沈敏鹤,刘鲁明,等.穴位注射治疗肺癌咯血40例[J].辽宁中医杂志,1992,3(2)：30.
[85]左秀玲.孔最穴在肺癌止痛中的应用[J].河北中医,1991,13(3)：4.
[86]王德炳.哈里森内科学[M].15版.北京：人民卫生出版社,2003：7011.
[87]张文怡.中医扶正培本法辅助肿瘤化疗47例[J].中医药临床杂志,2004,16(2)：117.
[88]曹利平,陈国庆.肺癌放化疗后中医诊疗思路[J].现代中医药,2012,32(3)：69-70.
[89]高佩芳,朱益敏.黄芪当归汤改善晚期肺癌化疗不良反应临床观察[J].山东中医药大学学报,2012,36(2)：127-128.
[90]李保健,吴晓阜,杨金山.归脾汤减轻非小细胞肺癌化疗骨髓抑制临床观察[J].山西中医,2011,27(9)：23.
[91]李艳秋,冯艳,王育强,等.生脉注射液对中晚期肺癌化疗患者免疫功能调节作用研究[J].中华中医药学刊,2007,25(2)：268-269.
[92]邓海滨,徐振晔,王中奇,等.抗瘤增效方对非小细胞肺癌化疗患者的近期疗效及其对免疫功能的影响[J].中医杂志,2011,52(10)：848-851.
[93]徐德新,高俊峰,刘今方,等.中药白山片抗肺癌作用的疗效观察和实验研究[J].辽宁中医杂志,1999,26(1)：44-46.
[94]张海青,李世业,付瑜,等.康莱特注射液治疗原发性肺癌的临床及病理学观察.中国肿瘤临床,1999,26(6)：477.
[95]冯利,林洪生.榄香烯对Lewis肺癌小鼠基底膜及细胞外间质影响的实验研究[J].中国肿瘤临床,2005,32(15)：891.
[96]Guruvayoorappan C, Kuttan G. Biophytum sensitivum(L). DC inhibits tumor cell invasion and metastasis through a mechanism involving regulation ofMMPs, prolyl hydroxylase, lysyl oxidase, nm23, ERK-1, ERK-2, STAT-1, and proinflammatory cytokine gene expression in metastatic lung tissue[J].Integrative Cancer Therapies,2008,7(1): 42.
[97]金念祖,茅力,朱燕萍,等.槐米提取物对小鼠Lewis市癌移植瘤细胞周期和PCNA表达的影响[J].中药新药与临床药理,2005,19(3)：71-74.
[98]谭永忠,戴国华,李军.茵陈素对肺癌细胞增殖和细胞周期的影响[J].中国药房,2001,12(5)：267-268.
[99]Van Erk MJ, Roepman P, van der Len de TR et al. Integrated as-sessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanism in colon can-cer cell in vitro [J]. Eur J Nutr,2004,30:1-14.
[100]许玲,刘嘉湘.益肺抗瘤饮抑制肺癌细胞增殖的实验研究[J].中国中西医结合杂志,1996,16(8)：486.
[101]韩明权,刘嘉湘,高虹,等.益肺抗瘤饮对实验性肺癌细胞周期及核酸和蛋白质合成的影响[J].中西医结合学报,2003,27(3)：35-38.
[102]刘海涛,戴锡孟.扶正方对LA795肺癌模型鼠EGFR和PCNA的影响[J].上海中医药杂志,2004,38(7)：48-50.
[103]汪伟民,汪波,刘荣玉,等.中药莪术油对小鼠Lewis肺癌抑制作用的实验研究.中国中医药科技,2003,10(6)：353-354.
[104]周彩虹,林洪生,黄启福,等.中药金安与顺铂诱导小鼠Lewis肺癌凋亡的研究[J].中国肿瘤,2003,12(3)：169-171.
[105]Hsu YL, Kuo PL, Lin CC. The proliferative inhibition and apoptotic:mechanism of Saikosaponin D in human non small cell lung cancer A549 cells [J]. Life Sei,2004,75(10): 1231-1242.
[106]黄冬生,陈会和,吴基良.姜黄素诱导人肺癌细胞凋亡的实验研究[J].咸宁医学院学报,2002,16(4)：252-255.
[107]马靖,符乃阳,李玉梅,等.甘草提取物体外选择性诱导几种人肿瘤细胞调亡[J].癌症,2001,20(8)：806-811.
[108]张会军.川芎嗪对人小细胞肺癌H446细胞增殖的抑制作用[J].肿瘤防治研究,2003,30(6)：452-454.
[109]赵婷秀,陈振发,邱幸凡,等.含中药莪术瓜蒌汤兔血清诱导人肺癌细胞凋亡的实验研究[J].微循环杂志,2005,15(1)：74-76.
[110]计磊,陈士壮,李西启,等.晚期非小细胞肺癌中药治疗前后肿瘤细胞凋亡的对比观察.上海医药,1997,(11)：30.
[111]唐炳华,崔巍,王继峰.承气生血方对小鼠Lewis肺癌抑制作用的实验研究.中国中医基础医学杂志,2005,11(8)：590-592.
[112]张芷旋,范羽,周清华,等.槐耳清膏对人高转移大细胞肺癌细胞L9981血管生成相关基因表达的影响[J].中国肺癌杂志,2006,9(2)：137-142
[113]杨国旺,王笑民,王征.固本消瘤胶囊抑制小鼠Lewis肺癌生长及抗血管生成研究[J].中国实验方剂学杂志,2004,10(5)：50-52.
[114]陈刚,徐晓玉,,严鹏科,等.川芎嗪和丹参对小鼠Lewis肺癌生长的抑制作用与抑制血管生成的关系[J].中草药,2004,35(3)：296.
[115]宋红,包素珍,郑小伟,等.血管内皮细胞生长因子在Lewis肺癌组织中表达的意义及十全大补汤对其干预作用[J].中华中医药杂志,2008,23(8)：684.
[116]程晓东,郭峰,刘嘉湘,等.中药扶正方对小鼠Lewis肺癌的疗效及其免疫学机理的研究[J].中国中西医结合杂志,1997,17(2)：88-90.
[117]林玲,章巧萍,俞丽霞,等.三根祛瘤方对Lewis肺癌等的抗瘤作用实验研究[J].浙江中医学院学报,1995,19(1)：37-39.
[118]张运芳,李俊,金涌,等.芪加合剂对荷瘤小鼠体液免疫功能的影响[J].安徽医科大学学报,2000,35(2)：118-120.
[119]薛兴奎,张玲,王芸,等.ICA、PJA逆转人高转移肺癌细胞Fas/FasL途径免疫逃逸机制的研究[J].中国免疫学杂志,2004,2(2)：102-105.
[120]刘海涛,戴锡孟.中药扶正合剂对LA795转移性肺癌小鼠的抑瘤作用和机制研究[J].江苏中医药,2004,25(10)：56-58.
[121]刘长青,周岱翰,陈林香,等.参芪固本方对小鼠Lewis肺癌的抑制作用[J].广州中医药大学学报,2006,23(5)：406.
[122]王晓瑜,苗利军.参芪平消胶囊对小鼠Lewis肺癌生长转移及免疫功能影响[J].中医研究,2005,18(9)：14-16.
[123]李大成等.三种中药制齐Ams-11、Fw-13、Tul-17逆转肿瘤细胞多药耐药性的研 究.华西医科大学学报.1998,29(1)：16.
[124]胡凯文等.中药活性成分抗耐药肿瘤细胞体外筛选研究.中国医药学报.1998,13(2)：10.
[125]戴馨仪等.固金磨积片抗肿瘤机理的研究.中药新药与临床药理.1997,8(3)：154.
[126]中国中西医结合研究会老年病中医专业委员.中医虚证辨证参考标准[J].中西医结合杂志,1986,10：595.
[127]Cao HC, Chen JK, Stewart J, et al. Distribution of p53 and K-ras mutation in human lung cancer tissues [J]. Carcinogenesis,1997,18 (3):473-478.
[128]Vahakankangas KH, Benne WP, Castren K, et al. p53 and K-ras mutations in lung cancers from former and never-smoking women [J]. Cancer Res,2001,61 (11):4350-4356.
[129]Ahrendt SA, Decker PA, Alawi EA, et al. Cigare e smoking is strongly asso-ciated with mutation of the K-ras gene in patients with primary adenocarci-noma of the lung [J]. Cancer, 2001,92 (6):1525-1530.
[130]Jones PA, Takai D. e role of DNA methylation in mammalian epigenetics[J]. Science, 2001,293 (5532):1068-1070.
[131]Wu JY, Wang J, Lai JC, et al. Association of O6-methylguanine-DNA meth-yltransferase(MGMT) promoter methylation with p53 mutation occurren-cein non-small cell lung cancer with di erent histology, gender, and smoking status. Ann Surg Oncol,2008, 15 (11):3272-3277.
[132]Kiyohara C, Yoshimasu K, Takayama K, et al. Lung cancer susceptibility:Are we on our way to identifying a high-risk group? [J] Future Oncol,2007,3 (6):617-627.
[133]Alexandrie AK, Sundberg MI, Seidegard J, et al. Genetic susceptibility to lung cancer with special emphasis on CYP1 Al and GSTM1:a study on host factors in relation to age at onset, gender and histological cancer types. Car-cinogenesis,1994,15 (9):1785-1790.
[134]Tang DL, Rundle A, Warburton D, et al. Associations between both genetic and environmental biomarkers and lung cancer:evidence of a greater risk of lung cancer in women smokers. Carcinogenesis,1998,19 (11):1949-1953.
[135]Kriek E, Rojas M, Alexandrov K, et al. Polycyclic aromatic hydrocarbon-DNA adducts in humans:relevance as biomarkers for exposure and cancer risk[J]. Mutat Res,1998,400 (1-2):215-231.
[136]Kure EH, Ryberg D, Hewer A, et al. p53 mutations in lung tumours:relation-ship to gender and lung DNA adduct levels [J]. Carcinogenesis,1996,17 (10):2201-2205.
[137]Liu Y, Inoue M, Sobue T, et al. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women:a large-scale population-based cohort study [J]. Int J Cancer,2005,117 (4):662-666.
[138]Weinberg OK, Marquez-Garban DC, Fishbein MC, et al. Aromatase inhibi-tors in human lung cancer therapy [J]. Cancer Res,2005,65 (24):11287-11291.
[139]Niikawa H, Suzuki T, Miki Y, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma[J]. Clin Cancer Res,2008,14(14):4417-4426.
[140]Hammoud Z, Tan B, Badve S, et al. Estrogen promotes tumor progression in a genetically de ned mouse model of lung adenocarcinoma [J]. Endocr Relat Cancer,2008,15 (2):475-483.
[141]Ivanova MM, Mazhawidza W, Dougherty SM, et al. Sex di erences in estro-gen receptor subcellular location and activity in lung adenocarcinoma cells [J]. Am J Respir Cell Mol Biol, 2010,42 (3):320-330.
[142]Ryk C, Kumar R, irumaran RK, et al. Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never-and ever smokers [J]. Lung Cancer,2006,54 (3):258-292.
[143]Divine KK, Gilliland FD, Crowell RE, et al. e XRCC1399 glutamine al-lele is a risk factor for adenocarcinoma of the lung [J]. Mutat Res,2001,461 (4):273-278.
[144]Dresler CM, Fratelli C, Babb J, et al. Gender di erences in genetic suscepti-bility for lung cancer [J]. Lung Cancer,2000,30 (3):153-160.
[145]Mollerup S, Ryberg D, Hewer A, et al. Sex di erences in lung CYP1A1 ex-pression and DNA adduct levels among lung cancer patients [J]. Cancer Res,1999,59(14):3317-3320.
[146]Yang XR, Wacholder S, Xu Z, et al. CYP1A1 polymorphism in relation to lung cancer in Chinese women [J]. Cancer Le,2004,214 (2):197-204.
[147]Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer:correla-tion with clinical response to getinib therapy [J]. Science,2004,304 (5676):1497-1500.
[148]夏小艳,玛依努尔.尼亚孜.HPV及HLA与宫颈癌关系研究进展[J].现代生物医学进展,2010,10(8)：1566-1569.
[149]Syrjanen KJ. HPV infections and lung cancer [J]. J Clin Pathol,2002,55(12):885-891.
[150]Willey JC, Broussoud A, Sleemi A, et al. Immortalization of normal human-bronchial epithelial cells by human papillomaviruses 16 or 18 [J]. Cancer Res,1991,51 (19): 5370-5377.
[151]Li YJ, Tsai YC, Chen YC, et al. Human papilloma virus and female lung ad-enocarcinoma [J]. Semin Oncol,2009,36 (6):542-552.
[152]Iwakawa R, Kohno T, Enari M, et al. Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma [J]. Cancer Sci,2010,101 (8): 1891-1896.
[153]李岩,孙思予,周卓.白术对小鼠胃排空及小肠推进功能影响的实验研究[J].辽宁医学杂志,1996,10(4)：186.
[154]马晓松,樊雪萍,陈忠,等.白术对离体豚鼠回肠收缩的影响[J].新消化病学杂志,1996,4(11)：603.
[155]李继承,吕志莲,石光和.腹膜孔的药物调节和计算机图象处理[J].中国医学科学院学报,1996,18(3)：219.
[156]关晓辉,曲娴,杨志萍,等.白术挥发油对小鼠免疫功能的影响[J].北华大学学报(自然科学版),2001,2(2)：122-123.
[157]毛俊浩.白术多糖对小鼠淋巴细胞功能的调节.免疫学杂志,1996,12(4)：233-236.
[158]吕圭源,李万里.白术抗衰老作用研究[J].现代应用药学,1996,13(5)：26-29.
[159]李怀荆,郭忠兴.白术水煎剂对老年小鼠抗衰老作用的影响[J].佳木斯医学学报,1996,19(1)：9.
[160]张宗,张鸿翔,史天良,等.白术挥发油的抗肿瘤作用的研究[J].肿瘤研究与临床,2006,18(12)：799-820.
[161]孙喜才,张玉五,连文太,等.健脾益气方841-A对小鼠S180实体瘤增殖的影响[J].陕西中医,1987,8(2)：90-91.
[162]孙喜才,张健,邱根全,等.白术抑瘤机理的探讨[J].陕西中医,1988,9(6)：282.
[163]浦含林,王正濂,黄巧娟,等.双白术内酯对豚鼠离体心房肌的作用[J].中国药理学通报.2000,16(1)：60-62.
[164]周海虹.白术提取物对子宫平滑肌作用的研究[J].安徽中医学院学报,1993,12(4)：39-40.
[165]周德文.术类的药理和药效[J].国外医药·植物药分册,1996,11(3)：120-122.
[166]冉先穗.中华药海[M].哈尔滨：哈尔滨出版社,1998：1588-1589.
[167]蒋天佑.白术的研究进展[J].中医药研究,1991,(5)：59-61.
[168]Endo K, et al. Chem Pharm Bull 1979,27 (12):2954.
[169]于辉,李春香,宫凌涛,等.甘草的药理作用概述[J].现代生物医学进展,2006,6(4)：77-79.
[170]海老名单三郎.甘草抗爱滋病作用研究[J].国外医学中医中药分册,1988,10(4)：16.
[171]王宪楷.甘草的抗菌作用研究[J].四川医学院学报,1980,2(2)：19.
[172]Okamoto T, Tanaka N, Vulto AG, et al. The protective effects of gly cyrrhizin on anti-fas antibody-induced hepatitis in mice[J]. Eur J Pharmacol,2000,387 (2):229.
[173]Van Rossum TG, Vulto AG, Hop WC, et al. Review article:gly cyrrhizin as a potential treatment for chronic hepatitis C[J]. Aliment Pharmacol Ther,1998,12 (2):199.
[174]Tsabota A. Corrbinecl ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection:a randomized controlled trial in 170 patients[J]. Eur J Gastroenterd Hepatol,1999,11 (10):1077.
[175]覃冬云,谢佳星,吴铁,等.甘草酸对血清和组织胺诱发的大鼠气道平滑肌细胞增生的影响[J].中国药理学通报,2004,20(8)：904-90.
[176]刘亚军,陈金和.甘草酸二铵对大鼠脑缺血再灌致神经细胞凋亡的保护作用[J].中国药理学通报,2005,21(1)：126-127.
[177]燕福生,宋学英,陈致清,等.甘草对人红细胞保护作用的研究[J].中国中药杂志,1996,21(11)：689-690.
[178]王明利,李春明,董萍,等.甘草黄酮治疗黄褐斑临床疗效观察[J].辽宁药物与临床,2003,6(3)：128.
[179]张敏.甘草皂甙与肺内SOD活性的研究[J].第三军医大学学报,1989,11(3)：183.
[180]关太辅.甘草在皮肤科的应用[J].日皮会志,1993,(7)：103.
[181]刘 阳,乔萍,朱玉琢.甘草对小鼠雄性生殖细胞遗传损伤的防护作用[J].中国公共卫生,2005,21(10)：1203-1204.
[182]宋晓亮,高广猷,叶丽红.山麦冬总皂甙对实验性心肌缺血的影响[J].中国药理学通报,1996,12(4)：329-332.
[183]黄厚才,倪正,蔡雪珠.麦冬对大鼠血小板聚集率的影响[J].上海实验动物科学,2001,21(3)：167-168.
[184]郭晶,陈非,李丽华,等.中药麦冬对D-半乳糖衰老模型大鼠血液流变性的影响[J].中国微循环,2002,6(4)：246-246
[185]王智杰,苟小林.麦冬降血糖作用的药效学研究[J].中医药学刊,2003,21(6)：898-899.
[186]段有金,王韶颖,三轮一智,等.五种中药对蛋白质非酶糖基化的抑制作用[J].中国糖尿病杂志,1998,6(4)：227-229.
[187]余伯阳,殷霞,荣祖元,等.短葶山麦冬皂甙C的药理活性研究[J].中国药科大学学报,1994,25(5)：286-288.
[188]陶站华,白书阁,白晶.麦冬对D半乳糖衰老模型大鼠的抗衰老作用研究[J].黑龙江医药科学,1999,22(4)：36-37.
[189]汤军,黄琦,徐志瑛,等.麦冬多糖的免疫活性研究[J].中国中医基础医学杂志,1998,4(9)：44-46.
[190]许燕萍,陈琪.麦冬多糖对大鼠脑缺血损伤的抗缺氧作用[J].镇江医学报.1996,6(3)：217-218.
[191]林晓明,冯建英,龙珠,等.银耳、茯苓、绞股蓝对小鼠免疫功能和清除自由 基的作用[J].北京医科大学学报,1995,27(6)：455-457.
[192]于凌,徐小东,吴警东,等.茯苓延缓大鼠皮肤衰老作用的实验研究[J].辽宁中医学院学报,2003,5(1)：52-53.
[193]金琦,曹静,王淑华.大剂量茯苓的药理作用及临床应用概况[J].浙江中医杂志,2003,38(9)：410-411.
[194]梁喜爱.中药猪苓、茯苓治疗肿瘤的药理功能新探[J].铁道医学,1992,20(4)：235.
[195]许津,吕 丁,钟启平,等.茯苓素对小鼠L1210细胞的抑制作用[J].中国医学科学院学报,1988,10(1)：45-49.
[196]尹镭,赵元昌,许瑞龄,等.茯苓对实验性肝硬变的治疗作用[J].山西医学院学报,1992,23(2)：101-103.
[197]潘明继.真菌多糖的抗肿瘤作用研究概况[J].中西医结合杂志,1985,5(2)：115.
[198]李电东,明秀英,甄永苏,等.茯苓素对抗癌药的增效作用[J].中国抗生素杂志,1990,15(1)：63-74.
[199]张国伟,夏求明.茯苓醇提取物抗心脏移植急性排斥反应的实验研究[J].中华器官移植杂志,2003,24(3)：169-171.
[200]孙博光,邱世翠,李波清,等.茯苓的体外抑菌作用研究[J].时珍国医国药,2003,14(7)：394.
[201]侯安继,彭施平,项荣,等.茯苓多糖的抗炎作用研究[J].中药药理与临床,2003,19(3)：15-16.
[202]尚 靖,敖秉臣,刘文丽,等.七种增白中药在体外对酪氨酸酶的影响[J].中国药学杂志,1995,30(11)：653-655.
[203]欧仕益.橘皮苷的药理作用[J].中药材,2002,36(7)：531-533.
[204]沈明勤,叶基正,常复蓉,等.陈皮水溶性总生物碱的升血压作用量效关系及药动力学研究[J].中国药学杂志,1997,32(2)：97-100.
[205]吉中强,宋鲁卿,高晓听,等.11种中药对大鼠血小板聚集和红细胞流变性的影响[J].山东中医杂志,2000,19(2)：107-108.
[206]吉中强,宋鲁卿,高晓听,等.15种理气中药体外对人血小板聚集的影响[J].中草药,2001,32(5)：428-430.
[207]王妹梅,何春美.陈皮提取物清除氧自由基和抗脂质过氧化[J].中国药科大学学报,1998,29(6)：462-464.
[208]钱士辉,王佾先,杨念云,等.陈皮提取物体内抗肿瘤作用及其对癌细胞增殖周期的影响[J].中国中药杂志,2003,28(12)：1167-1170.
[209]方玉复,魏玉平,丁香安,等.陈皮对浅部真菌的试管内抑菌实验及临床疗效观察[J].中国皮肤性病学杂志,1997,11(5)：275.
[210]林伸二.橘皮提取物抑制黑色素生成[J].国外医学·中医中药分册,2002,24(6)：368.
[211]樊英,丁自勉.陈皮等几种柑桔皮提取物对蚜、螨类虫杀虫活性初步研究[J].中国中药杂志,1995,20(7)：397-398.
[212]蔡周权,代勇,袁浩宁.陈皮挥发油的药效学实验研究[J].中国药业,2006,15(13)：29-30.
[213]王新嘉,何国芬.橙皮苷对STZ糖尿病大鼠肾脏功能和形态影响[J].中华内分泌代谢杂志,1996,12(1)：34-36.
[214]张文芝.陈皮水煎液对离体唾液淀粉酶活性的影响[J].辽宁中医药杂志,1989,(4)：30.
[215]李伟,郑天珍,瞿颂义,等.陈皮对小鼠胃排空及肠推进影响[J].中药药理与临床,2002,18(2)：22-23.
[216]官福兰,王汝俊,王建华,等.陈皮及橙皮苷对离体肠管运动影响[J].时珍国医国药,2002,13(2)：65-67.
[217]陈海玲,金佳鹤.施志明教授运用培土法治疗肺癌经验介绍[J].新中医.2007,39(5)：90-91.
[218]丁纪元, 孟昭琳. 黄芪四君子汤在晚期非小细胞肺癌化疗中的应用[J].浙江中西医结合杂志,2006,16(1)：28-29.
[219]朱伟伟,沈敏鹤.吴良村辨治肺癌经验[J].浙江中医杂志,2008,43(10)：571.
[220]方锦舒,毕蕾.王端平教授运用益气养阴解毒法治疗中晚期肺癌经验[J].中医学报,2010,25(147)：224-225.
[221]吴继.刘嘉湘教授治疗肺癌常用药对拾撷[J].中华中医药学刊,2010,28(6)：1154-1156.
[222]徐炎华.参麦注射液对晚期肺癌化疗增效减毒作用的临床研究[J].肿瘤,1996,16(S2)：358.
[223]吴小明.补肾健脾中药降低中晚期肺癌化疗毒副反应效果观察[J].中医药临床杂志.2010,22(5)：392-393.
[224]黄晓佳,曹勇.补肾益肺解毒方对大鼠诱发性肺癌免疫功能的影响[J].河北中医,2011,33(1)：108-110.
[225]喻清和,王鹏,邱志楠.益气补肾为主治疗肿癌患者术后化疗反应的临床研究[J].新中医,2009,41(3)：31-33.
[2]汪英,李锡春.恶性肿瘤放疗、化疗后的中医药应用体会[J].世界中医药,2009,3(4)：97-98.
[3]吴一龙,廖美琳,孙燕,等.中国肺癌临床指引(2005年版).人民卫生出版社,2005.
[4]刘嘉湘,现代中医药应用与研究大系[M].肿瘤科第一版.上海：上海中医药出版社,1996：120.
[5]李连弟,鲁风珠,张思维,等.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997：19(1)：3.
[6]周清华,孙燕.肺癌新理论新技术进展[M].第一版.成都：四川大学出版社,2003：3-7.
[7]李连弟,饶克勤.中国11市县肿瘤发病和死亡登记资料统计分析(1988年-1992年)[J].中国肿瘤,2000；9(10)：435-447.
[8]李连弟,饶克勤,张思维,等.中国12市县1993年-1997年肿瘤发病和死亡登记资料统计分析[J].中国肿瘤,2002：11(9)：497-50.
[9]张思维,陈万青,孔灵芝,等.中国部分市县1998-2002年恶性肿瘤的发病与死亡[J].中国肿瘤,2006：15(7)：430-448.
[10]张思维,陈万青,孔灵芝,等.中国部分市县2003年恶性肿瘤发病年度报告[J].中国肿瘤,2007：16(7)：494-507.
[11]陈万青,张思维,邹小农.中国肺癌发病死亡的估计和流行趋势研究[J].中国肺癌杂志,2010,13(5)：488-493.
[12]杨功焕,王俊芳,万霞,等.影响中国人群疾病死亡因素的定量分析[J].中华流行病学杂志,2005,26(12)：3212-3218.
[13]Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women:age, smok-ing, histology, performance status, stage, initial treatment and survival:Pop-ulation-based study of 20,561 cases[J]. Ann Oncol,2002,13 (7):1087-1093.
[14]Crespo-Leiro MG, Villa-Arranz A, Manito-Lorite N, et al. Lung cancer a erheart transplantation:results from a large multicenter registry[J]. Am J Trans-plant,2011,11 (5): 1035-1040.
[15]尧晓晴,孙世良,刘平,等.1,213例肺癌患者的人群分布特点[J].职业卫生与 病伤,2008,18(1)：9-10.
[16]Mills C A, Potrer M M. Tobacco smokinghabits and cancer of the mouth and respiratory system[J]. Cancer Res,1950,10 (9):539-542.
[17]Centers for Disease Control and Prevention. Tobacco use among adults-United States, 2005[J]. MMWR,2006,55 (42):1145-1148.
[18]Vineis P, Alavanja M, Buffler P, et al. Tobacco and cancer:recent epidemiological evidence[J]. JNCI,2004,96 (2):99-106.
[19]Vineis P, Airoldi L, Veglia F, et al. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study[J]. BMJ,2005,330 (7486):265-266.
[20]Yang P, Allen M S, Aubry M C, et al. Clinical features of 5,628 primary lung cancer patients:experience at Mayo Clinic from 1997 to 2003 [J]. Chest,2005,128 (1):452-462.
[21]杨功焕,马杰民,刘娜,等.中国人群2002年吸烟和被动吸烟的现况调查[J].中华流行病学杂志,2004,25(10)：837-840.
[22]Krinsky N I, Johnson E J. Carotenoidactions and their relation to health and idsease [J]. Mol Aspects Med,2005,26 (6):459-516.
[23]Ruano-Ravina A, Figueiras A, Freire-Garabal M, et al. Antioxidant Vitamins and risk of lung cancer [J]. Curr Pharm Des,2006,12 (5):599-613.
[24]Siems W, Wiswedel I, Saleno C, et al. β-Carotene breakdwom products may impair mitochondrial functions-potential side effects of higy-dose β-carotene supplementation [J]. J NutrBiochem,2005,16 (7):385-397.
[25]Schuller H M, Porter B, Riechert A, et al. Neuroendocrine lung carcinogenesis in hamsters is inhibited by green tea theophylline while the development of adenocarcinomas is promoted:implications for chemoprevention in smokers [J]. Lung Cancer,2004,45 (1): 11-18.
[26]Vittal R, Selvanayagam Z E, Sun Y, et al. Gene expression changes induced by geen tea polyphenol-epigallocatechin-3-gallate in human bronchial 21BES cells analyzed by DNA microarray[J]. Mol Cancer Ther,2004,3 (9):1091-1099.
[27]Sinha R, Kulldorff M, Swanson C A, et al. Dietary heterocyclic amines and the risk of lung cancer among Missouri women [J]. Cancer Res,2000,60 (14):3753-3756.
[28]高国福,姚树详,孙秀娣,等.云南锡矿工肺癌的队列研究[J].中国肺癌杂志,2002,5(2)：81-91.
[29]Essary L R, Vargas S O, Fletcher C D. Primary pleuropulmonary synovial sarcoma: reappraisal of a recently described anatomic subset [J]. Cancer,2002,94(2):459-469.
[30]Minna J D, Roth J A, Gazdar A F. Focus on lung cancer [J]. Cancer Cell,2002,1 (1):49-52.
[31]Hussain S P, Hofseth L J, Harris C C. Tumor suppressor genes:at the crossroads of molecular carcinogenesis, molecular epedemiology and human risk assessment [J]. Lung Cancer,2001,34 (Suppl2):7-15.
[32]Pfeifer G P, Denissenko M F, Olivier M, et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers [J]. Oncogene,2002,21 (48):7435-7451.
[33]Hainaut P, Olivier M, Pfeifer G P. TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke:Lessons from the I ARC TP53 mutation database [J]. Mutagenesis,2001,16 (6):551-553.
[34]吕嘉春,吴中亮,施侣元,等.核苷酸切除修复基因表达低下与肺癌的关系[J].中国公共卫生,2003,19(7)：780-782.
[35]Hirscha F R, Herbst R S, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy [J]. J Clin Oncol,2008,26 (20):3351-3357.
[36]Sequist L V, Bell D W, Lynch T J, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small lung cancer[J]. J Clin Oncol,2007,25 (5): 587-595.
[37]Ciardiello F, Torrora G. EGFR antagonists in cancer treatment[J]. N Engl J Med,2008, 358 (11):1160-1174.
[38]张德超,毛友生,黄国俊.中国肺癌外科治疗概况与进展[J].中国肺癌杂志,2005：8(6)：572-562.
[39]李佩文.肺癌综合诊疗学[M].第一版.北京：中国中医药出版社,2001：295-302.
[40]周清华,孙燕.肺癌新理论新技术进展[M].第一版.成都：四川大学出版社,2003：164-165.
[41]The international adjuvant lung cancer trial collaborative group. Cis Platinbased Adjuvant chemotherapy in Patients with completely reseeted non-Small cell lung cancer[J]. NEJM, 2004:3 (50):351-360.
[42]曾大雄,徐永健.非小细胞肺癌的化疗进展[J].世界临床药物,2009：30(4)：242-247.
[43]Roy S. Herbst Targeted Therapy in Non-Small Cell Lung Cancer. On-cology,2002, 16 (suppl9):19-24.
[44]张晓彤,李龙芸,王树兰,等.吉非替尼治疗晚期非小细胞肺癌疗效观察[J].中华结核和呼吸杂志,2005,25：180-183.
[45]王金万,孙燕,刘永煜,等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4)：283-290.
[46]程翔,童莉.癌生物治疗研究进展[J].现代中西医结合杂志,2006：15(6)： 829-831.
[47]廖美琳,赵家美,杨新法,等.肺癌[M].北京：中国医药科技出版社,2003.
[48]段庚仙.恶性肿瘤化疗的毒副作用及其防治[J].肿瘤研究与临床.2004,10(16)：353-354.
[49]庞香茹.中药治疗恶性肿瘤放化疗后骨髓抑制的临床研究[J].中医学报,2011,4(4)：393-394.
[50]何舒.化疗呕吐研究进展[J].宁夏医学杂志,2003,25(3)：12-16.
[51]刘欣荣,杨怀勇,唐盛得.如何减少放化疗治疗的副作用[M].2010年中国药学大会暨第十届中国药师周论文集.
[52]张娜,曹勇.恶性肿瘤化疗毒副反应从脾肾论治[J].新中医,2010,10(42)10：1-2.
[53]邓海滨,王中奇.徐振晔辨治肺癌经验[J].四川中医,2002,20(6)：1.
[54]赵炜.李佩文治疗肺癌的经验[J].北京中医,2002,21(6)：329.
[55]周晓园,陶凯.顾振东治疗肿瘤的经验[J].中医杂志,1999,40(7)：395.
[56]孙宏新,孙君.周宜强教授诊治肺癌经验[J].中国中医药信息杂志,2000,7(4)：68.
[57]陈延武,樊惠连.胡国良老中医临证经验总结[J].湖南中医杂志,1998,14(3)：27.
[58]洪广样.原发性支气管肺癌中医药治疗的探讨[J].江西中医药,1995,26(6)：3.
[59]骆文斌,吴承玉.肺癌病因病机研究[J].辽宁医药大学学报,2009,11(3)：16-17.
[60]田建辉,施志明.原发性支气管肺癌中医药治疗现状分析[J].四川中医,2003,21(1)：15-17.
[61]唐文秀,张宗歧,林红生,等.中医药治疗晚期原发性非小细胞肺癌的临床观察[J].中医杂志,1994,35(5)：283-285.
[62]刘嘉湘,施志明,徐振华,等.滋阴生津益气温阳法治疗晚期原发性肺腺癌的临床研究[J]中医杂志,1995,36(3)：155.
[63]蒋天佑.肺癌的辨治经验与体会[J].山西中医,2008,24(12)：3-5.
[64]陈锐深,张伦.肺癌578例辨证论治[J].亚洲医药,1997,12(5)：21.
[65]刘振东,吴林生.周维顺治疗肺癌经验[J].浙江中医学院学报,2004,3(28)：39-40.
[66]李东芳.中医辨证治疗晚期非小细胞肺癌32例临床观察[J].四川中医,2003,21(1)： 33.
[67]游捷,施志明.肺积方治疗非小细胞肺癌61例临床疗效评价[J].上海中医药杂志,2005,39(6)：17.
[68]孙玉清,史清华.中医药治疗中晚期肺癌33例[J].新中医,2005,37(8)：34.
[69]孙钢.刘嘉湘辨治肺癌的特色[J].中医杂志,2000,41(2)：75.
[70]范元芳,许秋萍,何伟涛.中医辨证综合治疗非小细胞肺癌临床疗效观察[J].中医药通报,2004,3(4)：47.
[71]陈乃杰.中医辨证配合化疗治疗晚期非小细胞肺癌41例[J].浙江中西医结合杂志,2000,10(1)：14.
[72]周维顺,吴良村,沈敏鹤.肺癌中医治则之我见[J].浙江中医学院学报,1992,16(2)：8-9.
[73]李佩文,张代钊,郝迎旭,等.平肺方治疗非小细胞肺癌109例临床观察[J].中医杂志,1995,36(2)：87.
[74]吴兰康.吴氏抗癌散结膏及抗癌扶正散治疗中晚期肺癌62例观察[J].实用中医药杂志,1994,10(3)：15.
[75]章永红,金树文.扶正软坚汤治疗肺癌临床观察[J].河南中医,1998,18(2)：44.
[76]刘长华.中药宁肺片治疗晚期肺癌临床观察[J].天津中医,1997,14(5)：208-209.
[77]李大鹏.康莱特注射液治疗原发性肺癌临床报告[J].中医杂志,1996,37(7)：413.
[78]张中华,任清宇.中药消癌平口服液治疗晚期肺癌的疗效观察[J].中华医学实践杂志,2007,6(7)：640-641.
[79]蔡红兵,代方国,闵清芬,等.中医药配合放疗治疗肺癌的临床研究[J].第一军医大学学报,2002,22(12)：1112.
[80]周荣耀,吴丽英,徐中伟,等.夏枯草注射液配合闭塞引流方法治疗肺癌胸水26例临床观察[J].中医杂志,1998,39(11)：662.
[81]杨爱光,王兴双.安肺膏外贴治疗肺癌[J].中医外治杂志,1996,13(2)：31.
[82]杨葆康,姜仁成,灵仙丹.熏吸疗法治疗中晚期肺癌66例[J].辽宁中医杂志,1994,21(7)：323.
[83]李永光,赵泉林,张盂香,等.气至病所治疗肺癌的初步研究[J].中国针灸,1989,2(3)：24.
[84]杨维泓,沈敏鹤,刘鲁明,等.穴位注射治疗肺癌咯血40例[J].辽宁中医杂志,1992,3(2)：30.
[85]左秀玲.孔最穴在肺癌止痛中的应用[J].河北中医,1991,13(3)：4.
[86]王德炳.哈里森内科学[M].15版.北京：人民卫生出版社,2003：7011.
[87]张文怡.中医扶正培本法辅助肿瘤化疗47例[J].中医药临床杂志,2004,16(2)：117.
[88]曹利平,陈国庆.肺癌放化疗后中医诊疗思路[J].现代中医药,2012,32(3)：69-70.
[89]高佩芳,朱益敏.黄芪当归汤改善晚期肺癌化疗不良反应临床观察[J].山东中医药大学学报,2012,36(2)：127-128.
[90]李保健,吴晓阜,杨金山.归脾汤减轻非小细胞肺癌化疗骨髓抑制临床观察[J].山西中医,2011,27(9)：23.
[91]李艳秋,冯艳,王育强,等.生脉注射液对中晚期肺癌化疗患者免疫功能调节作用研究[J].中华中医药学刊,2007,25(2)：268-269.
[92]邓海滨,徐振晔,王中奇,等.抗瘤增效方对非小细胞肺癌化疗患者的近期疗效及其对免疫功能的影响[J].中医杂志,2011,52(10)：848-851.
[93]徐德新,高俊峰,刘今方,等.中药白山片抗肺癌作用的疗效观察和实验研究[J].辽宁中医杂志,1999,26(1)：44-46.
[94]张海青,李世业,付瑜,等.康莱特注射液治疗原发性肺癌的临床及病理学观察.中国肿瘤临床,1999,26(6)：477.
[95]冯利,林洪生.榄香烯对Lewis肺癌小鼠基底膜及细胞外间质影响的实验研究[J].中国肿瘤临床,2005,32(15)：891.
[96]Guruvayoorappan C, Kuttan G. Biophytum sensitivum(L). DC inhibits tumor cell invasion and metastasis through a mechanism involving regulation ofMMPs, prolyl hydroxylase, lysyl oxidase, nm23, ERK-1, ERK-2, STAT-1, and proinflammatory cytokine gene expression in metastatic lung tissue[J].Integrative Cancer Therapies,2008,7(1): 42.
[97]金念祖,茅力,朱燕萍,等.槐米提取物对小鼠Lewis市癌移植瘤细胞周期和PCNA表达的影响[J].中药新药与临床药理,2005,19(3)：71-74.
[98]谭永忠,戴国华,李军.茵陈素对肺癌细胞增殖和细胞周期的影响[J].中国药房,2001,12(5)：267-268.
[99]Van Erk MJ, Roepman P, van der Len de TR et al. Integrated as-sessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanism in colon can-cer cell in vitro [J]. Eur J Nutr,2004,30:1-14.
[100]许玲,刘嘉湘.益肺抗瘤饮抑制肺癌细胞增殖的实验研究[J].中国中西医结合杂志,1996,16(8)：486.
[101]韩明权,刘嘉湘,高虹,等.益肺抗瘤饮对实验性肺癌细胞周期及核酸和蛋白质合成的影响[J].中西医结合学报,2003,27(3)：35-38.
[102]刘海涛,戴锡孟.扶正方对LA795肺癌模型鼠EGFR和PCNA的影响[J].上海中医药杂志,2004,38(7)：48-50.
[103]汪伟民,汪波,刘荣玉,等.中药莪术油对小鼠Lewis肺癌抑制作用的实验研究.中国中医药科技,2003,10(6)：353-354.
[104]周彩虹,林洪生,黄启福,等.中药金安与顺铂诱导小鼠Lewis肺癌凋亡的研究[J].中国肿瘤,2003,12(3)：169-171.
[105]Hsu YL, Kuo PL, Lin CC. The proliferative inhibition and apoptotic:mechanism of Saikosaponin D in human non small cell lung cancer A549 cells [J]. Life Sei,2004,75(10): 1231-1242.
[106]黄冬生,陈会和,吴基良.姜黄素诱导人肺癌细胞凋亡的实验研究[J].咸宁医学院学报,2002,16(4)：252-255.
[107]马靖,符乃阳,李玉梅,等.甘草提取物体外选择性诱导几种人肿瘤细胞调亡[J].癌症,2001,20(8)：806-811.
[108]张会军.川芎嗪对人小细胞肺癌H446细胞增殖的抑制作用[J].肿瘤防治研究,2003,30(6)：452-454.
[109]赵婷秀,陈振发,邱幸凡,等.含中药莪术瓜蒌汤兔血清诱导人肺癌细胞凋亡的实验研究[J].微循环杂志,2005,15(1)：74-76.
[110]计磊,陈士壮,李西启,等.晚期非小细胞肺癌中药治疗前后肿瘤细胞凋亡的对比观察.上海医药,1997,(11)：30.
[111]唐炳华,崔巍,王继峰.承气生血方对小鼠Lewis肺癌抑制作用的实验研究.中国中医基础医学杂志,2005,11(8)：590-592.
[112]张芷旋,范羽,周清华,等.槐耳清膏对人高转移大细胞肺癌细胞L9981血管生成相关基因表达的影响[J].中国肺癌杂志,2006,9(2)：137-142
[113]杨国旺,王笑民,王征.固本消瘤胶囊抑制小鼠Lewis肺癌生长及抗血管生成研究[J].中国实验方剂学杂志,2004,10(5)：50-52.
[114]陈刚,徐晓玉,,严鹏科,等.川芎嗪和丹参对小鼠Lewis肺癌生长的抑制作用与抑制血管生成的关系[J].中草药,2004,35(3)：296.
[115]宋红,包素珍,郑小伟,等.血管内皮细胞生长因子在Lewis肺癌组织中表达的意义及十全大补汤对其干预作用[J].中华中医药杂志,2008,23(8)：684.
[116]程晓东,郭峰,刘嘉湘,等.中药扶正方对小鼠Lewis肺癌的疗效及其免疫学机理的研究[J].中国中西医结合杂志,1997,17(2)：88-90.
[117]林玲,章巧萍,俞丽霞,等.三根祛瘤方对Lewis肺癌等的抗瘤作用实验研究[J].浙江中医学院学报,1995,19(1)：37-39.
[118]张运芳,李俊,金涌,等.芪加合剂对荷瘤小鼠体液免疫功能的影响[J].安徽医科大学学报,2000,35(2)：118-120.
[119]薛兴奎,张玲,王芸,等.ICA、PJA逆转人高转移肺癌细胞Fas/FasL途径免疫逃逸机制的研究[J].中国免疫学杂志,2004,2(2)：102-105.
[120]刘海涛,戴锡孟.中药扶正合剂对LA795转移性肺癌小鼠的抑瘤作用和机制研究[J].江苏中医药,2004,25(10)：56-58.
[121]刘长青,周岱翰,陈林香,等.参芪固本方对小鼠Lewis肺癌的抑制作用[J].广州中医药大学学报,2006,23(5)：406.
[122]王晓瑜,苗利军.参芪平消胶囊对小鼠Lewis肺癌生长转移及免疫功能影响[J].中医研究,2005,18(9)：14-16.
[123]李大成等.三种中药制齐Ams-11、Fw-13、Tul-17逆转肿瘤细胞多药耐药性的研 究.华西医科大学学报.1998,29(1)：16.
[124]胡凯文等.中药活性成分抗耐药肿瘤细胞体外筛选研究.中国医药学报.1998,13(2)：10.
[125]戴馨仪等.固金磨积片抗肿瘤机理的研究.中药新药与临床药理.1997,8(3)：154.
[126]中国中西医结合研究会老年病中医专业委员.中医虚证辨证参考标准[J].中西医结合杂志,1986,10：595.
[127]Cao HC, Chen JK, Stewart J, et al. Distribution of p53 and K-ras mutation in human lung cancer tissues [J]. Carcinogenesis,1997,18 (3):473-478.
[128]Vahakankangas KH, Benne WP, Castren K, et al. p53 and K-ras mutations in lung cancers from former and never-smoking women [J]. Cancer Res,2001,61 (11):4350-4356.
[129]Ahrendt SA, Decker PA, Alawi EA, et al. Cigare e smoking is strongly asso-ciated with mutation of the K-ras gene in patients with primary adenocarci-noma of the lung [J]. Cancer, 2001,92 (6):1525-1530.
[130]Jones PA, Takai D. e role of DNA methylation in mammalian epigenetics[J]. Science, 2001,293 (5532):1068-1070.
[131]Wu JY, Wang J, Lai JC, et al. Association of O6-methylguanine-DNA meth-yltransferase(MGMT) promoter methylation with p53 mutation occurren-cein non-small cell lung cancer with di erent histology, gender, and smoking status. Ann Surg Oncol,2008, 15 (11):3272-3277.
[132]Kiyohara C, Yoshimasu K, Takayama K, et al. Lung cancer susceptibility:Are we on our way to identifying a high-risk group? [J] Future Oncol,2007,3 (6):617-627.
[133]Alexandrie AK, Sundberg MI, Seidegard J, et al. Genetic susceptibility to lung cancer with special emphasis on CYP1 Al and GSTM1:a study on host factors in relation to age at onset, gender and histological cancer types. Car-cinogenesis,1994,15 (9):1785-1790.
[134]Tang DL, Rundle A, Warburton D, et al. Associations between both genetic and environmental biomarkers and lung cancer:evidence of a greater risk of lung cancer in women smokers. Carcinogenesis,1998,19 (11):1949-1953.
[135]Kriek E, Rojas M, Alexandrov K, et al. Polycyclic aromatic hydrocarbon-DNA adducts in humans:relevance as biomarkers for exposure and cancer risk[J]. Mutat Res,1998,400 (1-2):215-231.
[136]Kure EH, Ryberg D, Hewer A, et al. p53 mutations in lung tumours:relation-ship to gender and lung DNA adduct levels [J]. Carcinogenesis,1996,17 (10):2201-2205.
[137]Liu Y, Inoue M, Sobue T, et al. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women:a large-scale population-based cohort study [J]. Int J Cancer,2005,117 (4):662-666.
[138]Weinberg OK, Marquez-Garban DC, Fishbein MC, et al. Aromatase inhibi-tors in human lung cancer therapy [J]. Cancer Res,2005,65 (24):11287-11291.
[139]Niikawa H, Suzuki T, Miki Y, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma[J]. Clin Cancer Res,2008,14(14):4417-4426.
[140]Hammoud Z, Tan B, Badve S, et al. Estrogen promotes tumor progression in a genetically de ned mouse model of lung adenocarcinoma [J]. Endocr Relat Cancer,2008,15 (2):475-483.
[141]Ivanova MM, Mazhawidza W, Dougherty SM, et al. Sex di erences in estro-gen receptor subcellular location and activity in lung adenocarcinoma cells [J]. Am J Respir Cell Mol Biol, 2010,42 (3):320-330.
[142]Ryk C, Kumar R, irumaran RK, et al. Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never-and ever smokers [J]. Lung Cancer,2006,54 (3):258-292.
[143]Divine KK, Gilliland FD, Crowell RE, et al. e XRCC1399 glutamine al-lele is a risk factor for adenocarcinoma of the lung [J]. Mutat Res,2001,461 (4):273-278.
[144]Dresler CM, Fratelli C, Babb J, et al. Gender di erences in genetic suscepti-bility for lung cancer [J]. Lung Cancer,2000,30 (3):153-160.
[145]Mollerup S, Ryberg D, Hewer A, et al. Sex di erences in lung CYP1A1 ex-pression and DNA adduct levels among lung cancer patients [J]. Cancer Res,1999,59(14):3317-3320.
[146]Yang XR, Wacholder S, Xu Z, et al. CYP1A1 polymorphism in relation to lung cancer in Chinese women [J]. Cancer Le,2004,214 (2):197-204.
[147]Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer:correla-tion with clinical response to getinib therapy [J]. Science,2004,304 (5676):1497-1500.
[148]夏小艳,玛依努尔.尼亚孜.HPV及HLA与宫颈癌关系研究进展[J].现代生物医学进展,2010,10(8)：1566-1569.
[149]Syrjanen KJ. HPV infections and lung cancer [J]. J Clin Pathol,2002,55(12):885-891.
[150]Willey JC, Broussoud A, Sleemi A, et al. Immortalization of normal human-bronchial epithelial cells by human papillomaviruses 16 or 18 [J]. Cancer Res,1991,51 (19): 5370-5377.
[151]Li YJ, Tsai YC, Chen YC, et al. Human papilloma virus and female lung ad-enocarcinoma [J]. Semin Oncol,2009,36 (6):542-552.
[152]Iwakawa R, Kohno T, Enari M, et al. Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma [J]. Cancer Sci,2010,101 (8): 1891-1896.
[153]李岩,孙思予,周卓.白术对小鼠胃排空及小肠推进功能影响的实验研究[J].辽宁医学杂志,1996,10(4)：186.
[154]马晓松,樊雪萍,陈忠,等.白术对离体豚鼠回肠收缩的影响[J].新消化病学杂志,1996,4(11)：603.
[155]李继承,吕志莲,石光和.腹膜孔的药物调节和计算机图象处理[J].中国医学科学院学报,1996,18(3)：219.
[156]关晓辉,曲娴,杨志萍,等.白术挥发油对小鼠免疫功能的影响[J].北华大学学报(自然科学版),2001,2(2)：122-123.
[157]毛俊浩.白术多糖对小鼠淋巴细胞功能的调节.免疫学杂志,1996,12(4)：233-236.
[158]吕圭源,李万里.白术抗衰老作用研究[J].现代应用药学,1996,13(5)：26-29.
[159]李怀荆,郭忠兴.白术水煎剂对老年小鼠抗衰老作用的影响[J].佳木斯医学学报,1996,19(1)：9.
[160]张宗,张鸿翔,史天良,等.白术挥发油的抗肿瘤作用的研究[J].肿瘤研究与临床,2006,18(12)：799-820.
[161]孙喜才,张玉五,连文太,等.健脾益气方841-A对小鼠S180实体瘤增殖的影响[J].陕西中医,1987,8(2)：90-91.
[162]孙喜才,张健,邱根全,等.白术抑瘤机理的探讨[J].陕西中医,1988,9(6)：282.
[163]浦含林,王正濂,黄巧娟,等.双白术内酯对豚鼠离体心房肌的作用[J].中国药理学通报.2000,16(1)：60-62.
[164]周海虹.白术提取物对子宫平滑肌作用的研究[J].安徽中医学院学报,1993,12(4)：39-40.
[165]周德文.术类的药理和药效[J].国外医药·植物药分册,1996,11(3)：120-122.
[166]冉先穗.中华药海[M].哈尔滨：哈尔滨出版社,1998：1588-1589.
[167]蒋天佑.白术的研究进展[J].中医药研究,1991,(5)：59-61.
[168]Endo K, et al. Chem Pharm Bull 1979,27 (12):2954.
[169]于辉,李春香,宫凌涛,等.甘草的药理作用概述[J].现代生物医学进展,2006,6(4)：77-79.
[170]海老名单三郎.甘草抗爱滋病作用研究[J].国外医学中医中药分册,1988,10(4)：16.
[171]王宪楷.甘草的抗菌作用研究[J].四川医学院学报,1980,2(2)：19.
[172]Okamoto T, Tanaka N, Vulto AG, et al. The protective effects of gly cyrrhizin on anti-fas antibody-induced hepatitis in mice[J]. Eur J Pharmacol,2000,387 (2):229.
[173]Van Rossum TG, Vulto AG, Hop WC, et al. Review article:gly cyrrhizin as a potential treatment for chronic hepatitis C[J]. Aliment Pharmacol Ther,1998,12 (2):199.
[174]Tsabota A. Corrbinecl ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection:a randomized controlled trial in 170 patients[J]. Eur J Gastroenterd Hepatol,1999,11 (10):1077.
[175]覃冬云,谢佳星,吴铁,等.甘草酸对血清和组织胺诱发的大鼠气道平滑肌细胞增生的影响[J].中国药理学通报,2004,20(8)：904-90.
[176]刘亚军,陈金和.甘草酸二铵对大鼠脑缺血再灌致神经细胞凋亡的保护作用[J].中国药理学通报,2005,21(1)：126-127.
[177]燕福生,宋学英,陈致清,等.甘草对人红细胞保护作用的研究[J].中国中药杂志,1996,21(11)：689-690.
[178]王明利,李春明,董萍,等.甘草黄酮治疗黄褐斑临床疗效观察[J].辽宁药物与临床,2003,6(3)：128.
[179]张敏.甘草皂甙与肺内SOD活性的研究[J].第三军医大学学报,1989,11(3)：183.
[180]关太辅.甘草在皮肤科的应用[J].日皮会志,1993,(7)：103.
[181]刘 阳,乔萍,朱玉琢.甘草对小鼠雄性生殖细胞遗传损伤的防护作用[J].中国公共卫生,2005,21(10)：1203-1204.
[182]宋晓亮,高广猷,叶丽红.山麦冬总皂甙对实验性心肌缺血的影响[J].中国药理学通报,1996,12(4)：329-332.
[183]黄厚才,倪正,蔡雪珠.麦冬对大鼠血小板聚集率的影响[J].上海实验动物科学,2001,21(3)：167-168.
[184]郭晶,陈非,李丽华,等.中药麦冬对D-半乳糖衰老模型大鼠血液流变性的影响[J].中国微循环,2002,6(4)：246-246
[185]王智杰,苟小林.麦冬降血糖作用的药效学研究[J].中医药学刊,2003,21(6)：898-899.
[186]段有金,王韶颖,三轮一智,等.五种中药对蛋白质非酶糖基化的抑制作用[J].中国糖尿病杂志,1998,6(4)：227-229.
[187]余伯阳,殷霞,荣祖元,等.短葶山麦冬皂甙C的药理活性研究[J].中国药科大学学报,1994,25(5)：286-288.
[188]陶站华,白书阁,白晶.麦冬对D半乳糖衰老模型大鼠的抗衰老作用研究[J].黑龙江医药科学,1999,22(4)：36-37.
[189]汤军,黄琦,徐志瑛,等.麦冬多糖的免疫活性研究[J].中国中医基础医学杂志,1998,4(9)：44-46.
[190]许燕萍,陈琪.麦冬多糖对大鼠脑缺血损伤的抗缺氧作用[J].镇江医学报.1996,6(3)：217-218.
[191]林晓明,冯建英,龙珠,等.银耳、茯苓、绞股蓝对小鼠免疫功能和清除自由 基的作用[J].北京医科大学学报,1995,27(6)：455-457.
[192]于凌,徐小东,吴警东,等.茯苓延缓大鼠皮肤衰老作用的实验研究[J].辽宁中医学院学报,2003,5(1)：52-53.
[193]金琦,曹静,王淑华.大剂量茯苓的药理作用及临床应用概况[J].浙江中医杂志,2003,38(9)：410-411.
[194]梁喜爱.中药猪苓、茯苓治疗肿瘤的药理功能新探[J].铁道医学,1992,20(4)：235.
[195]许津,吕 丁,钟启平,等.茯苓素对小鼠L1210细胞的抑制作用[J].中国医学科学院学报,1988,10(1)：45-49.
[196]尹镭,赵元昌,许瑞龄,等.茯苓对实验性肝硬变的治疗作用[J].山西医学院学报,1992,23(2)：101-103.
[197]潘明继.真菌多糖的抗肿瘤作用研究概况[J].中西医结合杂志,1985,5(2)：115.
[198]李电东,明秀英,甄永苏,等.茯苓素对抗癌药的增效作用[J].中国抗生素杂志,1990,15(1)：63-74.
[199]张国伟,夏求明.茯苓醇提取物抗心脏移植急性排斥反应的实验研究[J].中华器官移植杂志,2003,24(3)：169-171.
[200]孙博光,邱世翠,李波清,等.茯苓的体外抑菌作用研究[J].时珍国医国药,2003,14(7)：394.
[201]侯安继,彭施平,项荣,等.茯苓多糖的抗炎作用研究[J].中药药理与临床,2003,19(3)：15-16.
[202]尚 靖,敖秉臣,刘文丽,等.七种增白中药在体外对酪氨酸酶的影响[J].中国药学杂志,1995,30(11)：653-655.
[203]欧仕益.橘皮苷的药理作用[J].中药材,2002,36(7)：531-533.
[204]沈明勤,叶基正,常复蓉,等.陈皮水溶性总生物碱的升血压作用量效关系及药动力学研究[J].中国药学杂志,1997,32(2)：97-100.
[205]吉中强,宋鲁卿,高晓听,等.11种中药对大鼠血小板聚集和红细胞流变性的影响[J].山东中医杂志,2000,19(2)：107-108.
[206]吉中强,宋鲁卿,高晓听,等.15种理气中药体外对人血小板聚集的影响[J].中草药,2001,32(5)：428-430.
[207]王妹梅,何春美.陈皮提取物清除氧自由基和抗脂质过氧化[J].中国药科大学学报,1998,29(6)：462-464.
[208]钱士辉,王佾先,杨念云,等.陈皮提取物体内抗肿瘤作用及其对癌细胞增殖周期的影响[J].中国中药杂志,2003,28(12)：1167-1170.
[209]方玉复,魏玉平,丁香安,等.陈皮对浅部真菌的试管内抑菌实验及临床疗效观察[J].中国皮肤性病学杂志,1997,11(5)：275.
[210]林伸二.橘皮提取物抑制黑色素生成[J].国外医学·中医中药分册,2002,24(6)：368.
[211]樊英,丁自勉.陈皮等几种柑桔皮提取物对蚜、螨类虫杀虫活性初步研究[J].中国中药杂志,1995,20(7)：397-398.
[212]蔡周权,代勇,袁浩宁.陈皮挥发油的药效学实验研究[J].中国药业,2006,15(13)：29-30.
[213]王新嘉,何国芬.橙皮苷对STZ糖尿病大鼠肾脏功能和形态影响[J].中华内分泌代谢杂志,1996,12(1)：34-36.
[214]张文芝.陈皮水煎液对离体唾液淀粉酶活性的影响[J].辽宁中医药杂志,1989,(4)：30.
[215]李伟,郑天珍,瞿颂义,等.陈皮对小鼠胃排空及肠推进影响[J].中药药理与临床,2002,18(2)：22-23.
[216]官福兰,王汝俊,王建华,等.陈皮及橙皮苷对离体肠管运动影响[J].时珍国医国药,2002,13(2)：65-67.
[217]陈海玲,金佳鹤.施志明教授运用培土法治疗肺癌经验介绍[J].新中医.2007,39(5)：90-91.
[218]丁纪元, 孟昭琳. 黄芪四君子汤在晚期非小细胞肺癌化疗中的应用[J].浙江中西医结合杂志,2006,16(1)：28-29.
[219]朱伟伟,沈敏鹤.吴良村辨治肺癌经验[J].浙江中医杂志,2008,43(10)：571.
[220]方锦舒,毕蕾.王端平教授运用益气养阴解毒法治疗中晚期肺癌经验[J].中医学报,2010,25(147)：224-225.
[221]吴继.刘嘉湘教授治疗肺癌常用药对拾撷[J].中华中医药学刊,2010,28(6)：1154-1156.
[222]徐炎华.参麦注射液对晚期肺癌化疗增效减毒作用的临床研究[J].肿瘤,1996,16(S2)：358.
[223]吴小明.补肾健脾中药降低中晚期肺癌化疗毒副反应效果观察[J].中医药临床杂志.2010,22(5)：392-393.
[224]黄晓佳,曹勇.补肾益肺解毒方对大鼠诱发性肺癌免疫功能的影响[J].河北中医,2011,33(1)：108-110.
[225]喻清和,王鹏,邱志楠.益气补肾为主治疗肿癌患者术后化疗反应的临床研究[J].新中医,2009,41(3)：31-33.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |